Genetic Testing for Retina Specialists

Seenu M. Hariprasad,Practical Retina Co-EditorIn December 2017, the U.S. Food and Drug Administration approved Luxterna (voretigene neparvovec-rzyl; Spark Therapeutics, Philadelphia, PA) as a new gene therapy to treat children and adult patients with RPE65 mutations resulting in vision loss. The availability of this landmark treatment has brought attention to the need for genetic testing by retina specialists.For this column, Kimberly Drenser, MD, PhD, and Edward H. Wood, MD, from William Beaumont Hospital in Royal Oak, MI, provide us with an overview of this important topic. They will begin

Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - May 21, 2018 Category: Opthalmology Authors: Edward H. Wood, MD Source Type: research